Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Western Digital Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Western Digital Corp trades at $562.53 (market cap $194.17B). The key difference: Western Digital Corp is far larger — about 24.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Western Digital Corp pays a 0.11% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | WDC | |
|---|---|---|
Market Cap | $8.04B | $194.17B |
Sector | Health | Technology |
52-Week High | $339.75 | $746.23 |
52-Week Low | $241.71 | $66.53 |
Enterprise Value | $7.85B | $192.51B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Western Digital (WDC) trades at $555.55, down 4.64% amid a sector-wide memory stock sell-off. The stock shows strong fundamentals with three consecutive quarterly EPS beats, a net income margin of 55.07%, and robust cash flow from operations of $1.69B in 2025. Technical indicators are bearish, with price near the pivot point of $551. Analyst sentiment remains overwhelmingly positive with a 72% buy rating and a $619.07 consensus price target, suggesting significant upside potential.
The outlook is supported by AI-driven storage demand and margin expansion, but near-term volatility from memory pricing cycles and competitive pressures poses risks. The stock's high valuation multiples require sustained earnings growth to justify further appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
